The inflammatory bowel disease market size is expected to grow by USD 7,687.43 million from 2022 to 2027 progressing at a CAGR of 5.77% as per the latest Technavio market research report. North America is estimated to account for 38% of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The rise in chronic gastrointestinal illnesses and escalating healthcare spending are propelling the expansion of the North American IBD market. Additionally, the market’s growth is spurred by pharmaceutical and biotechnology enterprises intensifying their research and development endeavours to create innovative IBD medications, alongside the prevalence of both global and regional market players. This trend is anticipated to persist during the forecast period. For more insights on the market share of various regions- Download a sample report in MINUTES
Inflammatory Bowel Disease Market: Increasing demand for biologics and targeted therapies
The increasing demand for biologics and targeted therapies are notably driving the market growth. Surgery is conducted as a remedy for ulcerative colitis and Crohn’s disease patients, aiming to alleviate symptoms. Due to the heightened vulnerability of individuals with Crohn’s disease to colon cancer, surgical interventions are at times employed to manage both ulcerative colitis and Crohn’s disease, reducing the risk of cancer development. However, the potential risks associated with gastrointestinal surgeries, such as infection, marginal ulceration, malabsorption, and strictures, could impede the widespread adoption of surgery as an IBD treatment approach. These heightened risks have prompted pharmaceutical and biopharmaceutical firms to shift their focus toward the development of biologics and sophisticated targeted therapies for gastrointestinal conditions like IBD. These biologics and targeted treatments are tailored to address specific proteins, tissues, or genetic factors contributing to IBD, signifying a transition towards their utilization as an alternative to traditional IBD therapies. This shift is expected to foster the growth of the global IBD market during the forecast period.
Inflammatory Bowel Disease Market: New Launches Of IBD Therapeutics
The new launches of IBD therapeutics are a primary trend in the inflammatory bowel disease market. Companies operating within the global IBD market are dedicating their efforts to the creation of novel therapeutic options, encompassing both small molecules and biologics, intended for the treatment of diverse forms of IBD. The advancement of cutting-edge treatments targeting inflammatory bowel diseases has been bolstered by heightened investments in research and development by pharmaceutical and biopharmaceutical entities, coupled with the introduction of new products. Such developments and an expansion in the number of new launches and product approvals of therapeutics for IBD are anticipated to fuel the market growth during the forecast period.
To know about more drivers, trends along with challenges – Download a sample now!
Some of the key Inflammatory Bowel Disease Market Players:
The inflammatory bowel disease market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
Abbott Laboratories, AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., Bausch Health Co. Inc., Baxter International Inc., Bayer AG, Biocon Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson and Johnson Services Inc.
What’s New? –
- Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
- Global competitiveness and key competitor positions
- Market presence across multiple geographical footprints – Strong/Active/Niche/Trivial – Buy the report!
Inflammatory Bowel Disease Market: Segmentation Analysis
This market research report segments the inflammatory bowel disease market by distribution channel (Offline and Online), type (Crohn disease and Ulcerative colitis), and geography (North America, Europe, Asia, and Rest of the World (ROW)).
- The market share growth by the offline segment will be significant during the forecast period. An integral component within the worldwide IBD market, the offline channel constitutes a vital conduit for the distribution of IBD therapeutics via conventional physical pharmacies and drugstores. While the global IBD market has observed an upsurge in the adoption of online distribution avenues, owing to their convenience and user-friendly nature, the influence of offline channels on the market remains significant. Consumers frequently gravitate towards procuring medications from brick-and-mortar establishments due to the assurance of immediate availability and the opportunity for direct interactions with pharmacists. This inclination supports the offline channel, enabling both well-established and emerging pharmaceutical enterprises to extend their reach to a broader base of the consumer.
For additional information on the market contribution of each segment – Grab an Exclusive Sample Report
Gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
Related Reports:
The anti-inflammatory therapeutics market size is estimated to grow at a CAGR of 6.7% between 2022 and 2027. The anti-inflammatory therapeutics market size is forecast to increase by USD 39.32 billion. This report extensively covers market segmentation by application (RA, psoriasis, and MS), drug class (anti-inflammatory biologicals, corticosteroids, and NSAIDs), and geography (North America, Europe, Asia, and Rest of World). The unmet need for safer biologics for RA is notably driving the anti-inflammatory drugs market growth.
The bronchiectasis drugs market size is estimated to grow at a CAGR of 9.98% between 2022 and 2027. The market size is forecast to increase by USD 326.01 million. This report extensively covers market segmentation by product (antibiotics, expectorants, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of the World (ROW)). The increasing cases of associated risks are the key factor driving the growth of the bronchiectasis drugs market.
| Inflammatory Bowel Disease Market Scope | |
| Report Coverage | Details |
| Base year | 2022 |
| Historic period | 2017-2021 |
| Forecast period | 2023-2027 |
| Growth momentum & CAGR | Accelerate at a CAGR of 5.77% |
| Market growth 2023-2027 | USD 7,687.43 million |
| Market structure | Fragmented |
| YoY growth 2022-2023 (%) | 4.92 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 38% |
| Key countries | US, Canada, UK, China, and India |
| Competitive landscape | Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
| Key companies profiled | Abbott Laboratories, AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., Bausch Health Co. Inc., Baxter International Inc., Bayer AG, Biocon Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson and Johnson Services Inc. |
| Market dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global inflammatory bowel disease market 2017 – 2021
- Exhibit 18: Historic Market Size – Data Table on global inflammatory bowel disease market 2017 – 2021 ($ million)
- 4.2 Distribution Channel Segment Analysis 2017 – 2021
- Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
- 4.3 Type Segment Analysis 2017 – 2021
- Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 – 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
- 4.5 Country Segment Analysis 2017 – 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
6 Market Segmentation by Distribution Channel
- 6.1 Market segments
- Exhibit 30: Chart on Distribution Channel – Market share 2022-2027 (%)
- Exhibit 31: Data Table on Distribution Channel – Market share 2022-2027 (%)
- 6.2 Comparison by Distribution Channel
- Exhibit 32: Chart on Comparison by Distribution Channel
- Exhibit 33: Data Table on Comparison by Distribution Channel
- 6.3 Offline – Market size and forecast 2022-2027
- Exhibit 34: Chart on Offline – Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Offline – Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Offline – Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Offline – Year-over-year growth 2022-2027 (%)
- 6.4 Online – Market size and forecast 2022-2027
- Exhibit 38: Chart on Online – Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Online – Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Online – Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Online – Year-over-year growth 2022-2027 (%)
- 6.5 Market opportunity by Distribution Channel
- Exhibit 42: Market opportunity by Distribution Channel ($ million)
- Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million)
7 Market Segmentation by Type
- 7.1 Market segments
- Exhibit 44: Chart on Type – Market share 2022-2027 (%)
- Exhibit 45: Data Table on Type – Market share 2022-2027 (%)
- 7.2 Comparison by Type
- Exhibit 46: Chart on Comparison by Type
- Exhibit 47: Data Table on Comparison by Type
- 7.3 Crohn disease – Market size and forecast 2022-2027
- Exhibit 48: Chart on Crohn disease – Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Crohn disease – Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Crohn disease – Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Crohn disease – Year-over-year growth 2022-2027 (%)
- 7.4 Ulcerative colitis – Market size and forecast 2022-2027
- Exhibit 52: Chart on Ulcerative colitis – Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Ulcerative colitis – Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Ulcerative colitis – Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Ulcerative colitis – Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by Type
- Exhibit 56: Market opportunity by Type ($ million)
- Exhibit 57: Data Table on Market opportunity by Type ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 59: Chart on Market share by geography 2022-2027 (%)
- Exhibit 60: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 61: Chart on Geographic comparison
- Exhibit 62: Data Table on Geographic comparison
- 9.3 North America – Market size and forecast 2022-2027
- Exhibit 63: Chart on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 64: Data Table on North America – Market size and forecast 2022-2027 ($ million)
- Exhibit 65: Chart on North America – Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on North America – Year-over-year growth 2022-2027 (%)
- 9.4 Europe – Market size and forecast 2022-2027
- Exhibit 67: Chart on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 68: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
- Exhibit 69: Chart on Europe – Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Europe – Year-over-year growth 2022-2027 (%)
- 9.5 Asia – Market size and forecast 2022-2027
- Exhibit 71: Chart on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on Asia – Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on Asia – Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
- Exhibit 75: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- 9.7 US – Market size and forecast 2022-2027
- Exhibit 79: Chart on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on US – Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on US – Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on US – Year-over-year growth 2022-2027 (%)
- 9.8 China – Market size and forecast 2022-2027
- Exhibit 83: Chart on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on China – Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on China – Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on China – Year-over-year growth 2022-2027 (%)
- 9.9 UK – Market size and forecast 2022-2027
- Exhibit 87: Chart on UK – Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on UK – Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on UK – Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on UK – Year-over-year growth 2022-2027 (%)
- 9.10 India – Market size and forecast 2022-2027
- Exhibit 91: Chart on India – Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on India – Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on India – Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on India – Year-over-year growth 2022-2027 (%)
- 9.11 Canada – Market size and forecast 2022-2027
- Exhibit 95: Chart on Canada – Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on Canada – Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Canada – Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 99: Market opportunity by geography ($ million)
- Exhibit 100: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 101: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 103: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 104: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 105: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 106: Matrix on vendor position and classification
- 12.3 AstraZeneca
- Exhibit 107: AstraZeneca – Overview
- Exhibit 108: AstraZeneca – Product / Service
- Exhibit 109: AstraZeneca – Key news
- Exhibit 110: AstraZeneca – Key offerings
- 12.4 Aurobindo Pharma Ltd.
- Exhibit 111: Aurobindo Pharma Ltd. – Overview
- Exhibit 112: Aurobindo Pharma Ltd. – Product / Service
- Exhibit 113: Aurobindo Pharma Ltd. – Key offerings
- 12.5 Baxter International Inc.
- Exhibit 114: Baxter International Inc. – Overview
- Exhibit 115: Baxter International Inc. – Business segments
- Exhibit 116: Baxter International Inc. – Key news
- Exhibit 117: Baxter International Inc. – Key offerings
- Exhibit 118: Baxter International Inc. – Segment focus
- 12.6 Bayer AG
- Exhibit 119: Bayer AG – Overview
- Exhibit 120: Bayer AG – Business segments
- Exhibit 121: Bayer AG – Key news
- Exhibit 122: Bayer AG – Key offerings
- Exhibit 123: Bayer AG – Segment focus
- 12.7 Eli Lilly and Co.
- Exhibit 124: Eli Lilly and Co. – Overview
- Exhibit 125: Eli Lilly and Co. – Product / Service
- Exhibit 126: Eli Lilly and Co. – Key news
- Exhibit 127: Eli Lilly and Co. – Key offerings
- 12.8 F. Hoffmann La Roche Ltd.
- Exhibit 128: F. Hoffmann La Roche Ltd. – Overview
- Exhibit 129: F. Hoffmann La Roche Ltd. – Business segments
- Exhibit 130: F. Hoffmann La Roche Ltd. – Key news
- Exhibit 131: F. Hoffmann La Roche Ltd. – Key offerings
- Exhibit 132: F. Hoffmann La Roche Ltd. – Segment focus
- 12.9 GlaxoSmithKline Plc
- Exhibit 133: GlaxoSmithKline Plc – Overview
- Exhibit 134: GlaxoSmithKline Plc – Business segments
- Exhibit 135: GlaxoSmithKline Plc – Key news
- Exhibit 136: GlaxoSmithKline Plc – Key offerings
- Exhibit 137: GlaxoSmithKline Plc – Segment focus
- 12.10 Johnson and Johnson Services Inc.
- Exhibit 138: Johnson and Johnson Services Inc. – Overview
- Exhibit 139: Johnson and Johnson Services Inc. – Business segments
- Exhibit 140: Johnson and Johnson Services Inc. – Key news
- Exhibit 141: Johnson and Johnson Services Inc. – Key offerings
- Exhibit 142: Johnson and Johnson Services Inc. – Segment focus
- 12.11 Merck and Co. Inc.
- Exhibit 143: Merck and Co. Inc. – Overview
- Exhibit 144: Merck and Co. Inc. – Business segments
- Exhibit 145: Merck and Co. Inc. – Key news
- Exhibit 146: Merck and Co. Inc. – Key offerings
- Exhibit 147: Merck and Co. Inc. – Segment focus
- 12.12 Novartis AG
- Exhibit 148: Novartis AG – Overview
- Exhibit 149: Novartis AG – Business segments
- Exhibit 150: Novartis AG – Key offerings
- Exhibit 151: Novartis AG – Segment focus
- 12.13 Pfizer Inc.
- Exhibit 152: Pfizer Inc. – Overview
- Exhibit 153: Pfizer Inc. – Product / Service
- Exhibit 154: Pfizer Inc. – Key news
- Exhibit 155: Pfizer Inc. – Key offerings
- 12.14 Sanofi
- Exhibit 156: Sanofi – Overview
- Exhibit 157: Sanofi – Business segments
- Exhibit 158: Sanofi – Key news
- Exhibit 159: Sanofi – Key offerings
- Exhibit 160: Sanofi – Segment focus
- 12.15 Sun Pharmaceutical Industries Ltd.
- Exhibit 161: Sun Pharmaceutical Industries Ltd. – Overview
- Exhibit 162: Sun Pharmaceutical Industries Ltd. – Product / Service
- Exhibit 163: Sun Pharmaceutical Industries Ltd. – Key offerings
- 12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 164: Teva Pharmaceutical Industries Ltd. – Overview
- Exhibit 165: Teva Pharmaceutical Industries Ltd. – Business segments
- Exhibit 166: Teva Pharmaceutical Industries Ltd. – Key news
- Exhibit 167: Teva Pharmaceutical Industries Ltd. – Key offerings
- Exhibit 168: Teva Pharmaceutical Industries Ltd. – Segment focus
- 12.17 Viatris Inc.
- Exhibit 169: Viatris Inc. – Overview
- Exhibit 170: Viatris Inc. – Business segments
- Exhibit 171: Viatris Inc. – Key news
- Exhibit 172: Viatris Inc. – Key offerings
- Exhibit 173: Viatris Inc. – Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 174: Inclusions checklist
- Exhibit 175: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 176: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 177: Research methodology
- Exhibit 178: Validation techniques employed for market sizing
- Exhibit 179: Information sources
- 13.5 List of abbreviations
- Exhibit 180: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio